Urgent Recall: Over 11,000 Bottles of Blood Pressure Meds Affected

URGENT UPDATE: More than 11,000 bottles of a widely used blood pressure medication have been recalled due to possible contamination, the U.S. Food and Drug Administration (FDA) confirmed. The recall, involving 11,136 bottles of Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP—marketed under the brand name Ziac—is a critical development for patients nationwide.

The recall affects bottles in 30-count, 100-count, and 500-count sizes distributed across the country. The urgency stems from testing of reserve samples that revealed traces of ezetimibe, a cholesterol-lowering drug produced by the same manufacturer, Glenmark Pharmaceuticals Inc.. This cross-contamination raises significant health concerns, prompting immediate action.

The recall was initiated on November 21, 2023, and was officially classified as a Class III risk level on December 1, 2023. A Class III recall indicates that exposure to or use of the affected product is not likely to cause adverse health consequences, but the FDA emphasizes the importance of reporting any side effects to healthcare professionals.

The affected lot numbers and their respective expiration dates are critical for consumers:
– Lot 17232401, exp 11/2025
– Lot 17240974, exp 05/2026

Individuals who have these medications should check their supplies immediately and contact their healthcare providers for guidance. The ongoing nature of this recall highlights the necessity for patients to remain vigilant regarding their medications.

As news of this recall spreads, it is essential for patients and healthcare professionals alike to stay informed. This situation underscores the importance of regular monitoring of medication supplies and the need for transparent communication from pharmaceutical companies.

For further updates, individuals are encouraged to follow the FDA’s official communications and consult with their healthcare providers. Stay tuned for more details as this situation develops.